Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

Maze Therapeutics, Inc. (NASDAQ:MAZE) appears in 137 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 104.9% of Maze Therapeutics's outstanding shares in December 2025, up from 93.8% in September 2025.
• They increased total shares held in Maze Therapeutics by 13.6% from the prior quarter, while the number of investors in MAZE stayed flat year over year.
• Of these 137 holders, 98 added to their stakes in Maze Therapeutics, 21 trimmed positions, and 18 made no changes.
• Institutional investors collectively held 48.02Mn shares in Maze Therapeutics as of December 2025, up by 5.75Mn shares quarter on quarter, and with no net change year over year.
• Janus Henderson Group Plc is the top holder of Maze Therapeutics as of December 31, 2025, with 5.72Mn shares representing 12.49% of outstanding stock.
• Top purchasers of MAZE stock for the quarter ending December 2025 included Paradigm Biocapital Advisors LP (2.74Mn), Janus Henderson Group Plc (2.58Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.18Mn), Cormorant Asset Management, LP (750.0K).
• The biggest sellers of Maze Therapeutics for the quarter ending December 2025 included Deep Track Capital, LP (768.88K), MARSHALL WACE, LLP (536.83K), Woodline Partners LP (385.0K), Foresite Capital Management IV, LLC (365.76K), ADAR1 Capital Management, LLC (308.97K).
• Business Quant data shows the 10 biggest positions in Maze Therapeutics as of December 2025 are held by Janus Henderson Group Plc (5.72Mn), Frazier Life Sciences Management, L.P. (4.57Mn), TRV GP IV, LLC (4.47Mn), ARCH Venture Management, LLC (4.12Mn), Deep Track Capital, LP (3.48Mn), Paradigm Biocapital Advisors LP (2.74Mn), BlackRock, Inc. (2.57Mn), a16z Capital Management, L.L.C. (1.7Mn), Venrock Adviser, LLC (1.6Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn).